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Purpose: To develop a reverse phase ultra-performance liquid chromatographic (RP-UPLC) method for 
the estimation of rabeprazole sodium in tablet formulations. 
Methods: Chromatographic separation was achieved on a Waters Acquity BEH C18 (50 x 2.1 mm, 
particle size 1.7 µm) column using an isocratic method with mobile phase composed of acetonitrile and 
phosphate buffer (pH 7.4) in the ratio of 35:65 (v/v). The flow rate was 0.4 ml/min, temperature of the 
column was maintained at ambient, injection volume was 5 µL and detection was made at 280 nm. The 
run time was as short as 2 min. Comparison of system performance with conventional HPLC was made 
with respect to analysis time, efficiency and sensitivity. 
Results: The developed method was linear for rabeprazole sodium from 0.03 - 30 µg/ml and the linear 
regression obtained was > 0.999. Precision, evaluated by intra- and inter-day assay,s had relative 
standard deviation (R.S.D) values within 1.5 %. Recovery data were in the range 98.0 - 101.5 % with 
R.S.D. values < 1.5 %.  
Conclusion: The method is precise, accurate, linear, robust and fast. The short retention time of 1.49 
min allows the analysis of a large number of samples in a short period of time and, therefore, should be 
cost-effective for routine analysis in the pharmaceutical industry.  
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INTRODUCTION 
 
Rabeprazole sodium (RAB) is a proton pump 
inhibitor with actions and uses similar to 
those of omeprazole. It is given orally as 
enteric coated rabeprazole tablets and 
normally taken in the morning. In the 
treatment of severe ulcerative gastro-
oesophogeal reflux desease, the usual dose 
is 20 mg once daily for 4 to 8 weeks; in the 
USA, a further 8-week course is permitted for 
healing of erosive oeophogistis [1]. 
Chemically rabeprazole is 2-[{(4)3-methoxy-
propoxy-3-methyl-2-pyridinyl} sulphinyl} 1-H 















Fig 1: Structure of rabeprazole 
 
Methods that have been reported for the 
determination of RAB include HPLC [2-5], 
thin layer chromatography (TLC) [6], UV 
spectrophotometry [7-9] and voltametry [10]. 
A method has been reported for the 
determination of the enantiomer and 
metabolite of RAB using HPLC [11] while 
some methods have also been published for 
the quantitative analysis of RAB in 
combination with other drugs [12-15].  
 
Ultra performance liquid chromatography 
(UPLC) is an emerging liquid 
chromatography technique which enables 
significant reduction in run time and solvent 
consumption. To the best of our knowledge, 
no UPLC method has been reported yet for 
the determination of RAB in pharmaceutical 
formulations.  
 
The aim of the present study was to develop 
a simple UPLC method for the determination 
of RAB in tablets and compare the results 




Chemicals and reagents 
 
Rabeprazole sodium (RAB) was received as 
a gift from Metro Labs Ltd, Baddi, India. RAB 
tablets was purchased from a local 
pharmacy. (Pepraz
®
, 10 mg, East West 
Pharma, India). HPLC grade acetonitrile was 
purchased from Merck India Ltd, Mumbai, 
India. High purity water was obtained using 
Millipore Milli-Q water purification system 
(Billerica, MA, USA). All other reagents were 
of analytical grade. 
 
Instrumentation and operating conditions 
 
The HPLC system used for initial 
chromatographic development was a Waters 
Alliance separation module with 2487 UV 
detector. A Waters symmetry C18 column 
(150 x 4.6mm, particle size 5µm) was used 
for separation. The mobile phase consisted of 
a mixture of phosphate buffer (pH 7.4) and 
acetonitrile in the ratio 65:35 (v/v). The flow 
rate was 1.0 ml/min while the injection 
volume was 20µL and detection was at 280 
nm. The column temperature was maintained 
at ambient. 
 
UPLC analysis was performed on a Waters 
Acquity UPLC system                    (Milford, 
USA) equipped with a binary solvent 
manager, an auto sampler, and a column 
manager composed of a column oven and 
tunable ultra violet (tuv) detector. 
Chromatographic separation was performed 
using a Waters Acquity BEH C18 (50 x 2.1 
mm, particle size 1.7 µm) column with the 
column temperature maintained at ambient 
while the mobile phase was the same as that 
used for HPLC. Flow rate was  0.4 ml/ min 
and the detector was set at 280 nm. Data 
acquisition, handling and instrument control 
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were performed with the aid of Empower 
software, version 1.0.  
 
Preparation of standards 
 
A stock solution of 1.0 mg/ml was prepared 
by dissolving an appropriate amount of RAB 
in 10mM potassium hydroxide solution. A 
working solution of 10 µg/ml
 
was prepared 
from this stock solution by serial dilution.  
 
Preparation of test solution from tablets 
 
Twenty tablets were weighed and powdered. 
An amount of the powder equivalent to 50 mg 
of RAB was taken into a 100 mL volumetric 
flask, and extracted with 10mM potassium 
hydroxide solution for 10 min. The solution 
was diluted suitably to 10 µg/ml and filtered 
through a 0.45 µm Millipore nylon filter paper. 
 
Dissolution sample preparation  
 
Labindia 2000 dissolution apparatus (a six-
tablets dissolution unit) (Labindia, Mumbai, 
India)  was used to test the dissolution of the 
tablets and hence generate test samples for 
analysis using the developed method. The 
dissolution test followed the procedure 
stipulated by United States Pharmacopoeia 
(USP) using apparatus 2 with paddles. The 
paddle speed was 100 rpm and the 
dissolution conditions followed US FDA 
(United States Food and Drug Administration) 
recommendation; the dissolution temperature 
of the media was maintained 37.0 ± 0.5 °C. 
For delayed release RAB tablets, the US 
FDA recommends dissolution test in 700 mL 
of 0.1N HCl for 2 h (samples were collected 
at intervals for assay of RAB), after which 
300 mL of 0.6M Tris-HCl buffer (pH 8.0) was 
added to the medium and the dissolution test 
continued for 45 min, during which samples 
were also withdrawn at intervals for assay of 
RAB). Auto sampling was used to collect 
samples (10 ml) at intervals over the test 
period. The samples were immediately 
filtered through a 0.45 µm Millipore nylon 
filter. The first 2 ml of the sample obtained 
each time during filtration was discarded in 
order to clean out the filter paper and thus 






Standard solution was used for the system 
suitability check. System suitability was 
analysed in terms of USP tailing factor (≤ 
2.0), theoretical plate counts (≥ 30000) and % 
R.S.D. (relative standard deviation) for five 




The precision of the method was evaluated 
by carrying out six independent assays of 
RAB test (tablet) sample against a qualified 
reference standard and the % R.S.D. of 
assay was calculated. The intermediate 
precision of the method was also evaluated 
using a different analyst, different columns of 
the same brand (Waters Acquity, BEH C18, 
50 x 2.1 mm, particle size 1.7 µm) and 
instrument (UPLC system, Waters Acquity) in 
the same laboratory. 
 
Limits of detection (LOD) and 
quantification (LOQ) 
 
LOD and LOQ for RAB were determined at 
signal-to-noise ratios of 3:1 and 10:1, 
respectively, by injecting series of dilute 
solution with known concentrations. Precision 
evaluation was also carried out at the LOQ 
level by injecting six individual preparations, 




Test solutions were prepared from RAB stock 
solution at ten concentration levels from LOQ 
to 300 % of analyte concentration (0.03, 0.5, 
1.0, 5.0, 7.5, 10.0, 12.5, 15.0, 20.0 and 30.0 
µg/ml). The peak area versus concentration 
data was treated by least squares linear 
regression analysis. 
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Accuracy 
 
The accuracy of the assay method was 
evaluated in triplicate at six concentration 
levels (between 10 and 150 %), i.e., 1.0, 3.0, 
5.0, 7.5, 10.0, and 15.0 µg/ml. Percent 




To determine the robustness of the 
developed method, experimental conditions 
were deliberately altered, and system 
suitability parameters were checked. The flow 
rate of the mobile phase was 0.4 ml/min. To 
study the effect of flow rate, flow rate was 
changed by 0.05 units from 0.35 to 0.45 
ml/min, the proportion of acetonitrile in the 
mobile phase 35 % was changed by ±3.5 %, 
and UV detection wavelength (280 nm) was 
changed ± 3nm. To study the effect of pH 
variation in the mobile phase, pH was altered 
by ±0.2 units, i.e., to 7.2 and 7.6. Changes in 
chromatographic parameters, i.e., theoretical 
plates, tailing factor and % R.S.D. were 






Based on International Conference on 
Harmonization (ICH) guidelines [16], the 
method is validated with regard to system 
suitability, linearity, accuracy, precision, LOD, 




The system suitability results for the 
proposed UPLC method are given in Table 1. 
The results proves that the optimized UPLC 
method fulfils these requirements within the 
USP accepted limits indicated in the 




The % R.S.D. of RAB assay during the 
method precision and the intermediate 
precision was 1.3 and 1.1, respectively, 
indicating good precision of the method. 
 
Table 1: System suitability results 
 










































* RT = retention time 
 
Limits of detection (LOD) and 
quantification (LOQ) 
 
LOD and LOQ for RAB were 0.007 and 0.03 
µg/ml, respectively. The LOQ  R.S.D. for the 
six preparations was 3.2 %, confirming the 
high precision of the LOQ at 0.03 µg/ml. 
Since the LOQ and LOD values of RAB are 
achieved at a very low level, this method can 
be suitable for cleaning validation in the 




The linearity of the calibration plot for the 
method was obtained over the calibration 
ranges tested, i.e., 0.03 - 30 µg/ml, and the 
correlation coefficient obtained was > 0.999, 
thus indicating excellent correlation between 
peak areas and concentrations of the analyte. 







Percent recovery of RAB samples ranged 
from 98.0 to 101.5, and % R.S.D. values 
were within 1.3 %, showing the good 
accuracy of the method. The result is shown 
in Table 2. 
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Robustness 
 
In all the deliberately varied chromatographic 
conditions, the assay results was between 98 
and 101 % and no significant changes were 
obtained in chromatographic parameters. 
This shows the robustness of the developed 
method. 
 






































Application of the developed method to 
commercial RAB tablets  
 
When the developed method was used to 
analyze a commercial brand of RAB tablet 
formulation, the mean recovery of six 
replicates was 99.69 % with % R.S.D. of 
0.52. The % recovery value indicates non-
interference from the excipients present in 
the dosage form. 
 
Application of the developed method to 
withdrawn RAB tablet dissolution samples 
indicates that mean release in acid (pH 1.2) 
mediun was 2.8 % (n = 6)) with % R.S.D of 
4.5 and  while in alkaline medium (pH 8.0 
buffer), the release was 97.2 % (n = 6) with % 
R.S.D of 3.2.  
 
Both the assay and dissolution test analyses 
were performed within 45 min thus indicating 
rapidity of analysis using UPLC method. 
 
DISCUSSION       
 
Method development and optimization 
 
The main aim of the developed method was 
to achieve separation and quantification of 
RAB using an isocratic mobile phase with 
UPLC system. Developing a UPLC method 
was to reduce the run time of the method and 
solvent consumption for routine analysis such 
as assay, dissolution and content uniformity 
during quality assurance. Detection of RAB 
was adequate at 280 nm.The initial trial was 
conducted using HPLC and chromatographic 
separation was obtained on a Waters 
symmetry C18 column (150 x 4.6mm, particle 
size 5µm). RAB is an acid labile compound 
and to avoid any degradation, a mobile phase 
with basic pH was selected. The mobile 
phase was optimized in the ratio of 10mM 
potassium dihydrogen phosphate buffer (pH 
7.4, adjusted with potassium hydroxide 
solution) to acetonitrile of 65: 35 (v/v) with a 
flow rate of 1.0 ml/min and injection volume 
20 µl. 
 
While developing the UPLC method, basic 
chromatographic conditions such as the 
column, solvents and UV detection employed 
in the HPLC method were taken into account. 
In selecting the UPLC column, its stability at 
the higher pH was taken into consideration to 
preserve the long life of the column. For RAB, 
the recommended Food and Drug 
Administration (FDA) medium for dissolution 
solution studies is pH 8.0; the optimized 
mobile phase pH used in the present study is 
also on the basic side. Most commercial C18 
columns are not stable at high pH on the 
longer run, thus shortening their life span. 
Waters Acquity BEH C18 (50 x 2.1mm, 
particle size 1.7 µm) column was found to be 
more suitable and stable at this pH. The peak 
was sharp and acceptable and the injection 
volume was reduced from 20 to 5 µl. The flow 
rate also is scaled down from 1.0 to 0.4 
ml/min. When these operating condition were 
applied to the developed method, a 
satisfactory peak was achieved for RAB, 
which eluted at around 1.49 min giving a total 
run time of 2 min. 
 
A comparison of HPLC and UPLC (Fig 2) 
with regard to elution time, sensitivity and 
other chromatographic parameters when the 
standard solution was injected, is shown in 
Table 3.The results indicate that the elution 
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time of RAB was reduced by about 9-fold 
compared to that for HPLC. Theoretical 
plates obtained for UPLC are about 8-fold 
higher than for HPLC which proves the higher 
separation efficiency of the UPLC than that of 




Fig 2: UPLC chromatograms of blank (a) and 
standard (b); also, HPLC chromatogram of 
standard (c) 
 
Table 3: Comparative operating parameters of 





















































































The new, isocratic RP-UPLC method proved 
to be simple, linear, precise, accurate, robust, 
rugged and rapid. The developed method 
was capable of giving faster elution, 
maintaining good separation more than that 
achieved with conventional HPLC. The short 
retention time of 1.49 min allows the analysis 
of a large number of samples in a short 
period of time and is therefore more cost-
effective for routine analysis in the 
pharmaceutical industries. The developed 
method was successfully applied to the 
dissolution study of RAB tablet. It is suitable 
for rapid and accurate quality control of RAB 
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